Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes.
Shabnam RadbakhshGeorge E BarretoAbigail R BlandAmirhossein SahebkarPublished in: BioFactors (Oxford, England) (2021)
Amyloidosis is a concept that implicates disorders and complications that are due to abnormal protein accumulation in different cells and tissues. Protein aggregation-associated diseases are classified according to the type of aggregates and deposition sites, such as neurodegenerative disorders and type 2 diabetes mellitus. Polyphenolic phytochemicals such as curcumin and its derivatives have anti-amyloid effects both in vitro and in animal models; however, the underlying mechanisms are not understood. In this review, we summarized possible mechanisms by which curcumin could interfere with self-assembly processes and reduce amyloid aggregation in amyloidosis. Furthermore, we discuss clinical trials in which curcumin is used as a therapeutic agent for the treatment of diseases linking to protein aggregates.
Keyphrases
- small molecule
- protein protein
- type diabetes
- clinical trial
- amino acid
- gene expression
- binding protein
- induced apoptosis
- glycemic control
- randomized controlled trial
- cardiovascular disease
- insulin resistance
- cell cycle arrest
- oxidative stress
- signaling pathway
- open label
- metabolic syndrome
- deep learning
- smoking cessation